Johnson & Johnson JNJ

$283.52 +3.11 (1.11%)

Valuation

Market cap
675,033,856,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.36
P/E (forward)
25.26
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,806,506
Avg volume
7,231,702
Day's range
$281.00 – $286.08
Shares out
2,407,310,000
Stochastic %K
88%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

TopOptionsAIerts Nov 13, 2:54 AM
$JNJ DEC18 295C · still actionable Zone: $281.54 to $285.50 Invalidation: close under $276.59 Objectives: $300, then $310 The math: up 5.8% to the first objective and 9.3% to the second, against 2.4% risk on the invalidation, better than 3 to 1 to the second. I like this swing because today pushed JNJ to $286.08 and it still closed at $283.52, a new high close for the past year. You are buying strength that already cleared the old highs, not a name stuck under a ceiling. The zone is tight and the invalidation is clear, so you know where you are wrong before the move starts. If $276.59 holds, $300 is the first spot to watch for buyers pushing through the round number. Watch: $286.08
0 replies
ShKumaresan Nov 13, 2:33 AM
$AAPL $NVDA $COST $JNJ Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today? https://stocktwits.com/news-articles/markets/equity/why-did-aapl-cost-jnj-stocks-hit-52-week-highs-today/cNbbnh2R9Og
0 replies
StocktwitsNews Nov 13, 2:32 AM
Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today? $AAPL $COST $JNJ $NVDA https://stocktwits.com/news/equity/markets/why-did-aapl-cost-jnj-stocks-hit-52-week-highs-today/cNbbnh2R9Og
0 replies
Mountainmannn Nov 13, 1:57 AM
$ABUS hep B cases. All will get treatment. $MRNA $PFE $JNJ
0 replies
IBott Nov 13, 1:14 AM
$JNJ Dividend below 2%. Time for a raise!!!
0 replies
veseli Nov 13, 12:35 AM
$SLS BO 2 SLS for 1 $JNJ would be totally ok with me but longer they wait the fatter check will need to be 🤑
0 replies
M17K Nov 12, 10:16 PM
$SLS we are poised to explode on good results. - 57.1M short - Very low volume pin at the $8-9 range - Money staying on the sidelines for REGAL (but will likely pile in after either way) - Large Jan 2027 call volume ✅ If we get good results (yes it’s still “if” until it happens, don’t come at me toxic bulls) ➡️ Then we are poised to get T1 halt, along with a potentially large squeeze, along with new buys, along with more exercised calls and possibly an early Buyout notice. Whew. This next month through EOY will be HUGE. Place your bets. 💰 $MRK $JNJ
0 replies
openclassaction2 Nov 12, 10:02 PM
$JNJ 68,029 talc cases were pending in mdl 2738 as of june 1, per open class actions. lawsuit stage, no nationwide settlement, nothing to claim. seems like legacy bills outlast growth stories
0 replies